ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,071.63
      0.02%
      US Tech 100
      16,867.60
      -0.80%
      Dow Jones
      38,460.92
      -0.11%
      Brent Oil
      87.31
      0.10%
      Bitcoin
      64,264.37
      -0.03%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX
      6. Mer Lyn Strat Ret Oil&Natl Gas (OGN)

      7. Mer Lyn Strat Ret Oil&Natl Gas (OGN) News

      OGN

      ML Str Ret Nts Ongi (OGN)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:OGN
      DateTimeSourceHeadlineSymbolCompany
      04/09/20248:13AMBusiness WireProlia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX1​​4が主要評価項目を達成NYSE:OGNOrganon and Co
      04/08/20242:31PMBusiness WireKlinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre EndpunkteNYSE:OGNOrganon and Co
      04/08/20242:31PMBusiness WireL'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primairesNYSE:OGNOrganon and Co
      04/08/20246:15AMBusiness WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024NYSE:OGNOrganon and Co
      04/08/20246:00AMBusiness WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary EndpointsNYSE:OGNOrganon and Co
      03/08/20249:01AMPR Newswire (Canada)On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's healthNYSE:OGNOrganon and Co
      03/08/20249:01AMPR Newswire (Canada)À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmesNYSE:OGNOrganon and Co
      03/01/20244:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
      03/01/20244:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
      03/01/20244:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
      03/01/20244:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
      02/26/20248:10AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:OGNOrganon and Co
      02/23/202411:46AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
      02/20/20248:00AMBusiness WireOrganon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National FormularyNYSE:OGNOrganon and Co
      02/15/20247:48AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
      02/15/20247:30AMBusiness WireOrganon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023NYSE:OGNOrganon and Co
      02/13/20244:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
      02/01/20247:30AMBusiness WireOrganon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024NYSE:OGNOrganon and Co
      01/10/20247:33AMBusiness WireOrganon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and OlderNYSE:OGNOrganon and Co
      01/08/20247:30AMBusiness WireOrganon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlookNYSE:OGNOrganon and Co
      12/21/20237:30AMBusiness WireOrganon To Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:OGNOrganon and Co
      12/19/20238:30AMBusiness WireOrganon et Lilly concluent un accord de commercialisation en Europe pour deux médicaments contre la migraineNYSE:OGNOrganon and Co
      12/19/20234:11AMBusiness WireOrganon と Lilly、ヨーロッパで 2 種類の片頭痛薬商業化契約を締結NYSE:OGNOrganon and Co
      12/18/20239:26PMBusiness WireOrganon und Lilly schließen Vermarktungsvereinbarung für zwei Migräne-Medikamente in EuropaNYSE:OGNOrganon and Co
      12/18/20237:30AMBusiness WireOrganon & Lilly Enter Commercialization Agreement in Europe for Two Migraine MedicinesNYSE:OGNOrganon and Co
      12/05/20234:31PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
      11/21/20237:30AMBusiness WireOrganon To Present at the Piper Sandler 35th Annual Healthcare ConferenceNYSE:OGNOrganon and Co
      11/07/20234:15PMGlobeNewswire Inc.Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®NYSE:OGNOrganon and Co
      11/03/20237:52AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:OGNOrganon and Co
      11/02/20237:38AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
       Showing the most relevant articles for your search:NYSE:OGN